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Abstract 
This paper is written in response to the linked editorial by Dr Geraghty about the PACE trial, 
which we led, implemented, and published. The PACE trial compared four treatments for 
people diagnosed with chronic fatigue syndrome (CFS). All participants in the trial received 
specialist medical care (SMC). The trial found that adding cognitive behaviour therapy (CBT) 
or graded exercise therapy (GET) to SMC was as safe as, and more effective than, adding 
adaptive pacing therapy (APT) or SMC alone. Dr Geraghty has challenged these findings. In 
this paper, we suggest that Dr Geraghty’s views are based on misunderstandings and 
misrepresentations of the PACE trial; these are corrected.   
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The PACE trial compared four treatments for people diagnosed with chronic fatigue 
syndrome (CFS) (White et al., 2011). A recent editorial about this trial (Geraghty, 2016) 
contains a number of inaccuracies which we now correct.      
1. Dr Geraghty states that “…there are accepted scientific procedures and standards that 
appear to have been neglected, or bypassed, by the PACE-Trial team”, although he has 
not said which procedures and standards we neglected or bypassed. The trial was 
extensively peer reviewed by the Medical Research Council, which funded it.  It followed 
the CONSORT guidance on how to report and conduct a high quality trial 
(http://www.consort-statement.org/). A Research Ethics Committee gave ethical 
approval, and it was overseen throughout by the independent Trial Steering Committee 
and Data Monitoring and Ethics Committee; patient members sat on the Trial 
Management and Steering Committees. The protocol was published some three years 
before the analysis began, and four years before the first outcome paper was published 
(White et al., 2007). The papers reporting the trial findings were peer reviewed before 
their publication in high impact journals, such as The Lancet (White et al., 2011). So far, 
we have published 16 papers from the trial (http://www.wolfson.qmul.ac.uk/current-
projects/pace-trial), as well as contributing data to an individual patient data Cochrane 
Collaboration review, which has  been submitted for publication. 
 
2. We reject the accusation that our “actions have arguably caused distress to patients,” for 
which Dr Geraghty offers no evidence. People with CFS and/or ME want treatments that 
help them to improve (Action for ME, 2011). In this ME charity member survey of NHS 
services, 85% of those surveyed wanted the charity to campaign to save these services 
and 92% wanted more such services; 46% had received CBT and 65% thought that CBT 
should be made available; 31% had received GET, and 48% thought it should be made 
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available (Action for ME, 2011). The PACE trial simply confirmed what previous smaller 
trials had already found (Edmonds et al., 2004; Price et al., 2008): that patients are more 
likely to get better with either CBT or GET than with other treatments or usual care.  
 
3. We reject the suggestion that the fact that we use these therapies for our patients and 
have tested them in previous trials is “a major source of investigator bias”. Clinical 
research often arises from questions thrown up by clinical practice.  The clinicians 
amongst us have dedicated our careers to care for thousands of patients with CFS/ME 
and we always want the best for them. We are therefore obliged to conduct trials to test 
the effectiveness and cost-effectiveness of treatments that we use. If Dr Geraghty’s 
proposal, that trials should only be conducted by investigators with no previous 
experience of an illness and its treatments, was followed, it would prevent any clinician 
or researcher from attempting to replicate or refute the results of their earliertrials. Whilst 
steps should always be taken to minimise bias, as we did, this suggestion is not 
sensible.  
 
4. In our long-term follow up paper we reported that the benefits of CBT and GET were 
maintained some two years after treatment (Sharpe et al., 2015). Dr Geraghty suggests 
that “The trial authors have since [the paper was published] argued that the SMC and 
APT groups [who improved over the follow up period], probably went to get CBT or GET 
privately after the end of the formal trial.” The reality is that we clearly reported within the 
paper the numbers of participants who went on to receive the additional therapies (most 
commonly CBT and GET), which were offered by trial NHS therapists to all participants 
who needed and wanted further help. 
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5. Regarding our paper on recovery Dr Geraghty stated that we defined it partially on the 
basis of “a patient reporting feeling ‘better’ or ‘much better’” when in reality  ratings of 
overall health as “much better “ or “very much better” counted towards being considered 
recovered on this measure.  
 
6. Dr Geraghty is also incorrect in his comments about the repeated use of the Freedom of 
Information Act (FOIA) to obtain trial information – “the PACE authors … refused to 
release data partly on the grounds that they viewed requesters as vexatious patients …”. 
Of the 46 FOIA requests that Queen Mary University of London have received, only two 
requests (not the requesters) were considered vexatious by the University; this view was 
confirmed by the Information Commissioner on appeal (Information Commissioners 
Office 2016a & b).  
 
7. We have repeatedly addressed the criticisms made in the editorial of the methods and 
analyses used in the PACE trial.  These can be found in blogs (Wessely, 2015, White et 
al., 2016a), journal correspondence, and as answers to frequently asked questions on 
the PACE trial website (http://www.wolfson.qmul.ac.uk/current-projects/pace-
trial#patients).  
 
8. In the editorial Dr Geraghty makes two criticisms, which we have not previously 
addressed. In the first one he states that “the effectiveness of cognitive behaviour 
therapy (CBT) and graded exercise therapy (GET), ….. , fell by two thirds” in a reanalysis 
of some of the trial data, and concludes that these “have left us with two versions of 
‘truth’ concerning the trial’s findings – the published analysis versus the recent analysis.” 
This is incorrect. Effectiveness was measured by comparing the mean scores for each of 
the two primary outcomes between treatment groups; the effect sizes varied between 0.5 
and 0.8 (moderate effect sizes), depending on the different comparisons (White et al., 
2011). In his editorial, Dr Geraghty has compared two different things: One is a 
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secondary post hoc analysis from the main paper, in which we reported the proportions 
of participants who improved by a clinically useful amount in both the primary outcomes 
(an improvement of 8 or more points for physical function and 2 points for fatigue), which 
equated to 61% for CBT and 59% for GET (White et al., 2011). The other is our 
reanalysis of some of the trial data comparing the proportions of participants who met a 
composite threshold for improvement (either improving by 50% on the primary outcomes 
or meeting a threshold for improvement) (Goldsmith et al., 2016). Using this composite 
outcome, 21% improved with GET and 20% with CBT; significantly more that with APT 
(9%) or SMC alone (10%) (Goldsmith et al, 2016). Dr Geraghty suggests that the 
effectiveness fell from 61% by one analysis method to 20% when using another method. 
It is no surprise that fewer participants are regarded as improved if more stringent criteria 
are applied. Since this has nothing to do with efficacy, it made no difference to our 
interpretation that “CBT and GET can safely be added to SMC to moderately improve 
outcomes for chronic fatigue syndrome, but APT is not an effective addition.” (White et 
al., 2011). The later analysis was described in our original protocol and then abandoned 
for the definitive analysis plan after statistical advice (Walwyn et al., 2013). This was 
because we accepted that using composite outcomes was complex, difficult to interpret, 
and incongruent with expert views (Senn and Julious, 2009). We changed this analysis 
with oversight committee approvals, and before outcome data were examined (White et 
al., 2011; Walwyn et al., 2013). 
 
9. The second criticism concerned our secondary analysis paper about recovery (White et 
al., 2013). Dr Geraghty states that “... some trial participants had reached the level 
required to be classified as improved or recovered at trial entry.”  This is incorrect; 3/640 
(<1%) of participants had scores within the normal population ranges for both fatigue and 
physical function at trial entry, which was only one of the criteria necessary to be 
considered as recovered. To meet the criteria for recovery, a participant also had to have 
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met additional criteria: no longer be considered a case of CFS (using the trial definition of 
CFS), and rated their overall health as “much” or “very much” better compared to trial 
entry.  No participants met the full criteria for recovery at trial entry. 
 
10. Regarding comments on the release of trial data, we wish to clarify that one of the main 
reason for our refusal to provide individual patient data to members of the public 
(following a Freedom of Information Act request) was that we do not have the consent of 
our participants to make their data publicly available. We were also concerned that 
patients might be personally identified by releasing the data. We support sharing data for 
the benefit of medical research and ultimately of patients (White et al., 2016b), as long 
as it is subject to certain guarantees – principally concerning confidentiality and an 
agreement not to attempt to identify participants. This is an ethical position, respecting 
patients’ rights, as we are required to do by research governance and the data protection 
law, and has been repeatedly supported by the Information Commissioner and 
Information Tribunal on all but one occasion.  
We stand firmly by the findings of the PACE trial, which, along with other studies, provide 
patients, healthcare professionals, and commissioners with the best evidence  that both CBT 
and GET are safe and effective treatments for this chronic and disabling illness. Others 
share this view (National Institute for Health and Clinical Excellence 2011; The Lancet 2011; 
NHS Choices 2011; The Lancet 2015). These findings are good news for patients who, in 
our experience, just want to get better. Of course, we need further trials, not only of CBT and 
GET, but also other treatments. To this end, we hope that editorials such as that by Dr 
Geraghty do not discourage others from doing such research. .  
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